News
MSD records one hit, one miss with TL1A drug tulisokibart
MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.
Thursday 29 October 2026
